What is Mineralys Therapeutics, Inc.'s increase (decrease) in accrued interest receivable, net?

Mineralys Therapeutics, Inc. (MLYS) reported increase (decrease) in accrued interest receivable, net of -$289K in Q1 2026.

How has Mineralys Therapeutics, Inc.'s increase (decrease) in accrued interest receivable, net changed year-over-year?

Mineralys Therapeutics, Inc.'s increase (decrease) in accrued interest receivable, net decreased by 455.8% year-over-year, from -$52K to -$289K.

Operating income-$45.3M-2.0%

Net income-$39.3M+6.8%

EPS (diluted)-$0.47+40.5%

Cash & equivalents$1.2M-14.6%

Total equity$638.1M+86.8%

Total assets$652.9M+83.9%

Operating cash flow-$39.5M+13.2%

CapEx$15.0K—

Free cash flow-$37.9M+43.3%

Market cap$2.27B+124%

Return on equity-31%-9.6pp

Current ratio44.3×+17.8×

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

What is Mineralys Therapeutics, Inc.'s increase (decrease) in accrued interest receivable, net?: Mineralys Therapeutics, Inc. (MLYS) reported increase (decrease) in accrued interest receivable, net of -$289K in Q1 2026.
How has Mineralys Therapeutics, Inc.'s increase (decrease) in accrued interest receivable, net changed year-over-year?: Mineralys Therapeutics, Inc.'s increase (decrease) in accrued interest receivable, net decreased by 455.8% year-over-year, from -$52K to -$289K.